Just When Flu Cases Dropped, Doctors Say They Noticed This Concerning Pattern

US flu activity has produced an estimated 20 million illnesses, 270,000 hospitalizations and 11,000 deaths so far this season (including 52 pediatric deaths), and CDC data show doctor visits and positive lab tests rising after a recent decline, prompting experts to warn of a likely 'second peak' as influenza A H3N2 continues and influenza B gains traction. For investors, the resurgence implies near-term upward pressure on healthcare utilization, potential staffing and absenteeism risks across consumer-facing sectors, and upside demand for vaccines and antivirals—monitor regional hospitalization trends and public-health measures for possible localized economic and supply impacts.

Analysis

Market structure: A renewed “second peak” favors diagnostics (Abbott ABT, Thermo Fisher TMO, Becton Dickinson BDX), retail immunizers (CVS, WBA) and manufacturers of antivirals/vaccines (Pfizer PFE, Moderna MRNA, GSK GSK, Sanofi SNY) for the next 1–3 months as testing, shot and outpatient treatment demand spikes. Travel/leisure (airlines AAL, UAL, hotels MAR, HLT) and discretionary retailers see near-term volume risk; pricing power for vaccines is limited by public procurement but private booster uptake can lift retail margins by mid-single-digits versus baseline.

Risk assessment: Tail risks include a more virulent drift variant triggering emergency procurement, temporary school/work closures, or supply-chain strain for vaccine fill/finish—each could move revenues ±10–30% for exposed names over weeks. Immediate (days) impacts will show in weekly CDC ILI and positive-lab-test deltas; short-term (weeks–months) manifests in quarterly revenues and inventories; long-term (quarters–years) is driven by vaccination policy changes and seasonality. Hidden dependency: overlapping COVID hospital load could push payor behavior and reserve recognition, compressing hospital/insurer margins unexpectedly.

Trade implications: Favor tactical long exposure to ABT and CVS for 2–3 month windows; buy 3-month call spreads (5–10% OTM) to cap risk, and hedge discretionary exposure with put spreads in airlines (AAL/UAL). Rotate out of high-beta leisure 3–6 weeks after CDC ILI shows a 50% decline from peak. Use weekly CDC FluView and a sustained >20% week-over-week rise in positive lab tests as buy triggers; unwind if tests drop 30% within 21 days.

Contrarian angles: Consensus underestimates regional divergence—names tied to states with early peaks (NY, CA) may already be priced for the surge while Midwest-focused distributors have runway. Diagnostics may be partly crowded; prefer vertically integrated players (ABT, TMO) over pure-play rapid-test names where margins erode. Historical parallels (2017–18 H3N2 late-wave) show 4–8 week tail revenue bumps, not structural upside—size positions accordingly.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Abbott Laboratories (ABT) using a 3-month call spread (buy 5% OTM, sell 15% OTM) to capture a testing demand surge; target return >30% if CDC positive-lab tests rise >20% WoW, stop-loss/close if tests fall 30% in 21 days.
• Initiate a 2% long equity position in CVS Health (CVS) to capture vaccine and OTC sales; hedge with a 1% notional short position in American Airlines (AAL) via a 3-month put spread (buy 15% OTM, sell 25% OTM). Exit CVS after a sustained 50% decline in national ILI from peak or after 3 months.
• Buy a 1–1.5% notional 3-month put spread on AAL (10–20% OTM) to protect travel exposure; increase hedge to 2.5% notionals if regional CDC FluView shows >30% hospitalization growth week-over-week for two consecutive weeks.
• Avoid adding large cap-weighted positions in vaccine developers (PFE, MRNA) until a material catalyst (federal emergency purchase order or FDA EUA change) occurs; monitor weekly FluView—enter 1.5–2% positions only after formal government procurement announcements within 30–60 days.